X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6645) 6645
Publication (474) 474
Book Review (402) 402
Conference Proceeding (17) 17
Book Chapter (16) 16
Dissertation (6) 6
Magazine Article (2) 2
Paper (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5618) 5618
humans (3502) 3502
male (2613) 2613
anilides - pharmacology (2489) 2489
animals (2341) 2341
anilides - therapeutic use (1445) 1445
female (1167) 1167
anilides (1030) 1030
middle aged (904) 904
rats (873) 873
mice (856) 856
aged (826) 826
prostatic neoplasms - drug therapy (683) 683
anilides - administration & dosage (680) 680
pharmacology & pharmacy (638) 638
oncology (617) 617
anilides - chemistry (583) 583
anilides - adverse effects (569) 569
abridged index medicus (542) 542
adult (535) 535
cell line, tumor (515) 515
nitriles (510) 510
prostate cancer (508) 508
tosyl compounds (508) 508
cancer (463) 463
anilides - metabolism (436) 436
biochemistry & molecular biology (433) 433
dose-response relationship, drug (422) 422
antineoplastic agents - therapeutic use (417) 417
time factors (410) 410
chemistry, organic (408) 408
pyridines - therapeutic use (396) 396
kinetics (393) 393
androgen antagonists - therapeutic use (385) 385
prostatic neoplasms - pathology (371) 371
anilides - chemical synthesis (368) 368
urology & nephrology (353) 353
structure-activity relationship (351) 351
research (325) 325
treatment outcome (319) 319
expression (318) 318
aged, 80 and over (313) 313
chemistry (307) 307
ppar gamma - antagonists & inhibitors (300) 300
analysis (298) 298
antineoplastic agents - pharmacology (297) 297
androgen antagonists - pharmacology (296) 296
encainide (294) 294
ppar gamma - metabolism (294) 294
article (284) 284
care and treatment (279) 279
signal transduction - drug effects (279) 279
activation (274) 274
chemistry, medicinal (274) 274
pyridines - pharmacology (271) 271
chemistry, multidisciplinary (270) 270
cells, cultured (263) 263
bicalutamide (258) 258
cell proliferation - drug effects (255) 255
molecular structure (255) 255
receptors, androgen - metabolism (243) 243
nitriles - pharmacology (239) 239
anilides - pharmacokinetics (238) 238
in vitro techniques (233) 233
tosyl compounds - pharmacology (225) 225
cell biology (224) 224
apoptosis (215) 215
prostatic neoplasms - metabolism (215) 215
carcinoma (213) 213
ligands (212) 212
rats, sprague-dawley (211) 211
catalysis (207) 207
therapy (206) 206
hydrogen-ion concentration (205) 205
nitriles - therapeutic use (204) 204
drug therapy, combination (202) 202
endocrinology & metabolism (200) 200
thiazolidinediones - pharmacology (197) 197
chemical phenomena (195) 195
tosyl compounds - therapeutic use (195) 195
anilides - toxicity (193) 193
apoptosis - drug effects (191) 191
disease models, animal (190) 190
dogs (188) 188
signal transduction (187) 187
cells (182) 182
clinical trials as topic (178) 178
carcinoma, basal cell - drug therapy (177) 177
metastasis (175) 175
flutamide - pharmacology (174) 174
skin neoplasms - drug therapy (174) 174
administration, oral (173) 173
cell line (169) 169
prostate-specific antigen - blood (168) 168
stereoisomerism (168) 168
anti-arrhythmia agents - therapeutic use (166) 166
growth (166) 166
derivatives (165) 165
toxicology (164) 164
androgen receptor (163) 163
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6045) 6045
German (212) 212
Japanese (79) 79
Italian (78) 78
Russian (70) 70
French (65) 65
Chinese (33) 33
Spanish (21) 21
Polish (15) 15
Czech (14) 14
Ukrainian (9) 9
Norwegian (5) 5
Portuguese (5) 5
Danish (4) 4
Swedish (4) 4
Dutch (3) 3
Hungarian (3) 3
Slovak (3) 3
Croatian (2) 2
Finnish (2) 2
Hebrew (2) 2
Bulgarian (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Materials Science & Engineering C, ISSN 0928-4931, 02/2017, Volume 71, pp. 954 - 964
In the present study, we designed Bicalutamide (BCT) and Hesperetin (HSP) co-loaded self nano-emulsifying drug delivery system (SNEDDS) to encounter the... 
Reactive oxygen species | Bicalutamide | Hesperetin | Antioxidant | Toxicity | Prostate cancer | MATERIALS SCIENCE, BIOMATERIALS | LYMPHATIC TRANSPORT | DRUG-DELIVERY | INDUCED APOPTOSIS | IMPROVED ORAL BIOAVAILABILITY | DROPLET SIZE | NANOPARTICLES | SYSTEMS SNEDDS | PROSTATE-CANCER | MCF-7 CELLS | ANTITUMOR EFFICACY | Prostatic Neoplasms - metabolism | Prostatic Neoplasms - pathology | Hesperidin - adverse effects | Nitriles - pharmacology | Anilides - adverse effects | Humans | Anilides - chemistry | Rats | Male | Tosyl Compounds - chemistry | Anilides - pharmacokinetics | Nitriles - pharmacokinetics | Rats, Sprague-Dawley | Tosyl Compounds - pharmacokinetics | Tosyl Compounds - pharmacology | Tosyl Compounds - adverse effects | Animals | Anilides - pharmacology | Hesperidin - chemistry | Nitriles - chemistry | Hesperidin - pharmacology | Nitriles - adverse effects | Hesperidin - pharmacokinetics | Prostatic Neoplasms - drug therapy | Drugs | Heat shock proteins | Drug delivery systems | Analysis | Vehicles | Clathrin | Fluorescence | Drug delivery | Optimization | Antioxidants | Endocytosis | Biocompatibility | Hepatotoxicity | Formulations | Thermogravimetric analysis | Lung diseases | Markers | Bioavailability | Fibrosis | In vivo methods and tests | Prostate | Cancer | Acute toxicity | Biochemical markers | Index Medicus | Encounters | Globules | Materials science | Nanostructure
Journal Article
Nature, ISSN 0028-0836, 03/2017, Volume 543, Issue 7647, pp. 728 - 732
A significant fraction of patients with advanced prostate cancer treated with androgen deprivation therapy experience relapse with relentless progression to... 
BREAST-CANCER | IMMUNE-SYSTEM | THERAPY | MULTIDISCIPLINARY SCIENCES | MOUSE | DOUBLE-BLIND | PHASE-3 TRIAL | TYROSINE KINASE INHIBITOR | SUPPRESSOR-CELLS | MYELOID CELLS | CHECKPOINT BLOCKADE | Anilides - therapeutic use | Immunotherapy - methods | Humans | Prostatic Neoplasms, Castration-Resistant - immunology | Male | Myeloid-Derived Suppressor Cells - drug effects | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Prostatic Neoplasms, Castration-Resistant - pathology | Quinolines - pharmacology | Myeloid-Derived Suppressor Cells - cytology | Prostatic Neoplasms, Castration-Resistant - therapy | Female | Imidazoles - therapeutic use | Cytokines - immunology | Disease Models, Animal | Pyridines - therapeutic use | Tumor Microenvironment - drug effects | Myeloid-Derived Suppressor Cells - immunology | Cytokines - metabolism | Imidazoles - pharmacology | Lymphocytes, Tumor-Infiltrating - drug effects | Drug Synergism | Tumor Microenvironment - immunology | Animals | Signal Transduction - drug effects | CD8-Positive T-Lymphocytes - drug effects | Anilides - pharmacology | Mice | Pyridines - pharmacology | Quinolines - therapeutic use | CD8-Positive T-Lymphocytes - immunology | Chimera | Lymphocytes, Tumor-Infiltrating - immunology | Care and treatment | Metastasis | Prostate cancer | Analysis | Immunotherapy | Patient outcomes | Cancer therapies | Tumors | Index Medicus
Journal Article
Journal of the American Chemical Society, ISSN 0002-7863, 08/2010, Volume 132, Issue 31, pp. 10842 - 10846
Journal Article
Nature, ISSN 0028-0836, 10/2018, Volume 562, Issue 7727, pp. 429 - 433
Despite the efficacy of Hedgehog pathway inhibitors in the treatment of basal cell carcinoma (BCC)(1) , residual disease persists in some patients and may... 
STEM-CELLS | VISMODEGIB | HAIR FOLLICLE | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION | KERATINOCYTES | OPEN-LABEL | SKIN | DIFFERENTIATION | CARCINOMA | BASAL-CELL | Anilides - therapeutic use | Skin Neoplasms - drug therapy | Humans | Epidermal Cells - metabolism | Hedgehog Proteins - metabolism | Smoothened Receptor - metabolism | Stem Cells - metabolism | Hair Follicle - pathology | Epidermal Cells - drug effects | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Carcinoma, Basal Cell - pathology | Hedgehog Proteins - antagonists & inhibitors | Carcinoma, Basal Cell - metabolism | Skin Neoplasms - metabolism | Hair Follicle - drug effects | Animals | Wnt Signaling Pathway - drug effects | Anilides - administration & dosage | Signal Transduction - drug effects | Cell Differentiation - drug effects | Hair Follicle - metabolism | Anilides - pharmacology | Carcinoma, Basal Cell - drug therapy | Epidermal Cells - pathology | Stem Cells - drug effects | Stem Cells - pathology | Cell Proliferation - drug effects | Mice | Pyridines - pharmacology | Basal cell carcinoma | Enzyme inhibitors | Research | Genetic transcription | Oncology, Experimental | Cancer | Chromatin | Transcription factors | Substance abuse treatment | Wnt protein | Medical treatment | Genomics | Stem cell transplantation | Epidermis | Activation | Genomes | Gene expression | Enhancers | Inhibitors | Transcription activation | Stem cells | Tumors | Index Medicus
Journal Article
Journal Article
Journal of Organic Chemistry, ISSN 0022-3263, 06/2019, Volume 84, Issue 12, pp. 8112 - 8120
In the presence of (S,S)-Trost ligand and (allyl-Pd-Cl)(2) catalyst, the reaction of allyl acetate with the anionic species prepared from various... 
CHEMISTRY, ORGANIC | ACTIVE ATROPISOMERIC ANILIDES | ASYMMETRIC ALLYLIC ALKYLATION | SELECTIVITY
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 296 - 304
Cabozantinib is an inhibitor of tyrosine kinases, including MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase II... 
Objective response rate | Randomised discontinuation trial | Cabozantinib | Vascular endothelial growth factor receptor | Progression-free survival | Solid tumour | DESIGN | EVEROLIMUS | CANCER | RENAL-CELL CARCINOMA | ONCOLOGY | GROWTH | AGENTS | INHIBITOR | United States | Anilides - adverse effects | Humans | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Early Termination of Clinical Trials | Pyridines - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Pyridines - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Neoplasms - enzymology | Neoplasms - mortality | Treatment Outcome | Disease Progression | Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Anilides - administration & dosage | Belgium | Taiwan | Israel | Neoplasms - pathology | Tyrosine | Care and treatment | Endothelial growth factors | Lung cancer | Product development | Metastasis | Prostate cancer | Ovarian cancer | Endothelium | Ovarian carcinoma | Hepatocellular carcinoma | Kinases | Metastases | Axl protein | Anticancer properties | Confidence intervals | Randomization | Castration | Expansion | Vascular endothelial growth factor | Hypertension | Melanoma | Non-small cell lung carcinoma | Diarrhea | Fatigue | Breast cancer | Conversion | Disease control | Patients | Studies | Antitumor activity | Solid tumors | Prostate | Tumors | Cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 07/2012, Volume 20, Issue 13, pp. 4020 - 4031
Journal Article
Thyroid, ISSN 1050-7256, 10/2014, Volume 24, Issue 10, pp. 158 - 1514
Journal Article